PD-L1 detection on circulating melanoma cells

Joseph W. Po; Yafeng Ma; Bavanthi Balakrishnar; Daniel Brungs; Farhad Azimi; Adam Cooper; Erin Saricilar; Vinay Murthy; Paul de Souza; Therese M. Becker

doi:10.1007/978-1-0716-1205-7_17

PD-L1 detection on circulating melanoma cells

Joseph W. Po, Yafeng Ma, Bavanthi Balakrishnar, Daniel Brungs, Farhad Azimi, Adam Cooper, Erin Saricilar, Vinay Murthy, Paul de Souza, Therese M. Becker

Western Sydney University

Research output: Chapter in Book / Conference Paper › Chapter

1 Citation (Scopus)

Abstract

The advent of personalized medicines targeting cell signaling pathways has radically improved melanoma patient outcomes. More recently, immune-modulating therapies disrupting the PD-1/PD-L1 axis have become a powerful tool in the treatment of a range of melanoma, showing a profound improvement in the overall survival outcomes. However, immune checkpoint inhibitors (ICIs) are associated with considerable toxicities and appear to only be efficacious in a subset of melanoma patients. Therefore, there is an urgent need to identify biomarkers that can determine if patients will or will not respond to ICI therapy. Here, we describe an optimized method for analyzing PD-L1 expression on circulating melanoma cells following immunomagnetic enrichment from patient blood samples.

Original language	English
Title of host publication	Melanoma: Methods and Protocols
Editors	Kristian M. Hargadon
Place of Publication	U.S.
Publisher	Humana Press
Pages	223-233
Number of pages	11
ISBN (Electronic)	9781071612057
ISBN (Print)	9781071612040
DOIs	https://doi.org/10.1007/978-1-0716-1205-7_17
Publication status	Published - 2021

Bibliographical note

Publisher Copyright:
© 2021, Springer Science+Business Media, LLC, part of Springer Nature.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-0716-1205-7_17

Cite this

@inbook{acff5141097845a1a1e9970a84a060a5,

title = "PD-L1 detection on circulating melanoma cells",

abstract = "The advent of personalized medicines targeting cell signaling pathways has radically improved melanoma patient outcomes. More recently, immune-modulating therapies disrupting the PD-1/PD-L1 axis have become a powerful tool in the treatment of a range of melanoma, showing a profound improvement in the overall survival outcomes. However, immune checkpoint inhibitors (ICIs) are associated with considerable toxicities and appear to only be efficacious in a subset of melanoma patients. Therefore, there is an urgent need to identify biomarkers that can determine if patients will or will not respond to ICI therapy. Here, we describe an optimized method for analyzing PD-L1 expression on circulating melanoma cells following immunomagnetic enrichment from patient blood samples.",

author = "Po, {Joseph W.} and Yafeng Ma and Bavanthi Balakrishnar and Daniel Brungs and Farhad Azimi and Adam Cooper and Erin Saricilar and Vinay Murthy and {de Souza}, Paul and Becker, {Therese M.}",

note = "Publisher Copyright: {\textcopyright} 2021, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2021",

doi = "10.1007/978-1-0716-1205-7_17",

language = "English",

isbn = "9781071612040",

pages = "223--233",

editor = "Hargadon, {Kristian M.}",

booktitle = "Melanoma: Methods and Protocols",

publisher = "Humana Press",

}

TY - CHAP

T1 - PD-L1 detection on circulating melanoma cells

AU - Po, Joseph W.

AU - Ma, Yafeng

AU - Balakrishnar, Bavanthi

AU - Brungs, Daniel

AU - Azimi, Farhad

AU - Cooper, Adam

AU - Saricilar, Erin

AU - Murthy, Vinay

AU - de Souza, Paul

AU - Becker, Therese M.

PY - 2021

Y1 - 2021

N2 - The advent of personalized medicines targeting cell signaling pathways has radically improved melanoma patient outcomes. More recently, immune-modulating therapies disrupting the PD-1/PD-L1 axis have become a powerful tool in the treatment of a range of melanoma, showing a profound improvement in the overall survival outcomes. However, immune checkpoint inhibitors (ICIs) are associated with considerable toxicities and appear to only be efficacious in a subset of melanoma patients. Therefore, there is an urgent need to identify biomarkers that can determine if patients will or will not respond to ICI therapy. Here, we describe an optimized method for analyzing PD-L1 expression on circulating melanoma cells following immunomagnetic enrichment from patient blood samples.

AB - The advent of personalized medicines targeting cell signaling pathways has radically improved melanoma patient outcomes. More recently, immune-modulating therapies disrupting the PD-1/PD-L1 axis have become a powerful tool in the treatment of a range of melanoma, showing a profound improvement in the overall survival outcomes. However, immune checkpoint inhibitors (ICIs) are associated with considerable toxicities and appear to only be efficacious in a subset of melanoma patients. Therefore, there is an urgent need to identify biomarkers that can determine if patients will or will not respond to ICI therapy. Here, we describe an optimized method for analyzing PD-L1 expression on circulating melanoma cells following immunomagnetic enrichment from patient blood samples.

UR - https://hdl.handle.net/1959.7/uws:68250

U2 - 10.1007/978-1-0716-1205-7_17

DO - 10.1007/978-1-0716-1205-7_17

M3 - Chapter

SN - 9781071612040

SP - 223

EP - 233

BT - Melanoma: Methods and Protocols

A2 - Hargadon, Kristian M.

PB - Humana Press

CY - U.S.

ER -

PD-L1 detection on circulating melanoma cells

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this